New Lilly Tirzepatide vs. Tresiba Ph3 Pivotal Study (SURPASS-3)

A new tirzepatide vs. Tresiba Ph3 T2DM pivotal trial (SURPASS-3) has been observed on CT.gov. This is the second tirzepatide Ph3 T2DM study supporting its global regulatory approvals. Recall, in November 2018, Lilly initiated SURPASS-4 (vs. glargine in T2DM patients with increased CV risk). Lilly has also recently initiated two Ph3 Japanese studies (SURPASS-J-mono and SURPASS-J-combo). Below, FENIX provides thoughts on SURPASS-3 and potential insight into the trial design.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.